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Abstract: Assumptions surrounding the kidney as a target for accumulation of ochratoxin A 
(OTA) are addressed because the contribution of the toxin in blood seems invariably to 
have been ignored. Adult rats were maintained for several weeks on toxin-contaminated 
feed. Using standard perfusion techniques, animals were anaesthetised, a blood sample was 
taken, one kidney was ligated, and the other kidney perfused with physiological saline  
in situ under normal blood pressure. Comparative analysis of OTA in pairs of kidneys 
showed marked reduction in the perfused organ in the range 37%–98% (mean 75%), 
demonstrating the general efficiency of perfusion supported also by histology, and 
implying a major role of blood in the total OTA content of kidney. Translation of OTA 
values in plasma to whole blood, and its predicted contribution as a 25% vascular 
compartment in kidney gave values similar to those in non-perfused kidneys. Thus, 
apparent ‘accumulation’ of OTA in kidney is due to binding to plasma proteins and long 
half-life in plasma. Attention should be re-focused on whole animal pharmacokinetics 
during chronic OTA exposure. Similar principles may be applied to DNA-OTA adducts 
which are now recognised as occurring in blood; application could also extend to other 
nephrotoxins such as aristolochic acid. Thus, at least, quantitative reassessment in 
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urological tissues seems necessary in attributing adducts specifically as markers of 
potentially-tumourigenic exposure. 
Keywords: perfusion in vivo; ochratoxin A; renal vasculature; ochratoxin accumulation; 
DNA adducts; aristolochic acid  
 
1. Introduction 
Ochratoxin A (OTA) is a well-known food-borne mycotoxin, for which the rat kidney is a 
significant experimental target, potentially evident both in the short-term concerning nephropathy and, 
after chronic exposure, as renal carcinoma. Several toxicity mechanisms may contribute to the former 
to diffuse cytotoxicity, according to dose. However, although currently unclear, for the latter,  
the mechanism for the highly-focal tumourigenesis may be more specific. In all cases, access of 
circulating OTA to renal parenchyma from the vasculature is important for all toxic expressions.  
This can at least partly be satisfied by the role of kidney as a principal organ of OTA excretion,  
in which several thousand independent nephrons function in parallel and via which OTA and its 
metabolites are known to be eliminated.  
In blood, most of the circulating OTA is bound to serum albumins so that it is only the small  
disassociated component of free OTA molecules that are available for excretion, during which access 
to potential sites of tumourigenesis can occur. 
The aim of the present study was to seek quantitative experimental evidence concerning the extent 
to which OTA concentration measured in whole kidneys of rats exposed chronically to dietary toxin is 
located within the renal vasculature. To date, this seems not to have been considered, according to the 
current literature, when commenting on OTA measured in kidney and blood plasma, or in reviews  
(e.g., [1]). Therefore, the strategy has been to compare the OTA content of kidneys from rats that have 
been given OTA contaminated feed for several weeks after isolating one kidney and surgically 
perfusing the other with a physiological solution. Blood plasma taken concurrently provided the 
measure of circulating OTA concentration. Necessarily, in the present context, there are general 
assumptions that the two kidneys in a rat have similar histological architecture, have similar arterial 
supply, and share excretory function in a reasonably equable way. Organ perfusion in situ under 
terminal anaesthesia is an established procedure for replacing vascular content while maintaining 
normal in vivo intravascular pressure, typically, for example, to ensure penetration of histological 
fixative to maintain lumen conformation within and around nephrons [2] and to avoid fixation artefacts 
in the brain due to restricted access of fixative [3,4]. For the present purpose, it is also important to 
minimise compression of cortical capillaries by the elasticity of the renal capsule by allowing blood 
pressure to decline slowly. Perfusion efficiency may vary for technical reasons, but this can be 
monitored subsequently by assessing absence of capillary erythrocytes in histological sections.  
Elegant three-dimensional imaging of rat kidney by micro-computed tomography has recognised an 
approximately 25% v/v vascular component [5,6], a finding that is particularly relevant here to 
interpreting any relationship between measured OTA amounts in blood plasma and kidney. 
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2. Results 
The study focuses on the situation within individuals and therefore tabulated findings (Table 1) 
show both individual data and gender group means where relevant. Generally, the measured OTA 
values in plasma were seven- to eight-fold higher than those in the normal (non-perfused) kidney. 
Qualitative monitoring of technical efficiency of flushing blood from the renal vasculature (Figure 1), 
assessed by histology of a small portion of each perfused kidney, clearly demonstrated the degree of 
success according to the reduction in the erythrocyte population that is naturally abundant in  
non-perfused kidney (Figure 1A). There was consistent correlation between the degree of perfusion 
efficiency predicted from histology (Figure 1B–D) and the percent efficiency values calculated from 
subsequent measurement of OTA in the perfused organs are described below (Table 1). 
Table 1. Concentrations of OTA in paired perfused and non-perfused kidneys of male and 
female rats given dietary toxin, indicating perfusion efficiency and the estimated OTA 
content of kidneys according to the predicted size of the vascular compartment. 
OTA in Plasma 
(µg/mL) 
Estimated  
OTA in Blood 
(µg/mL) 
Estimated OTA  
in Kidney at 25% 
Vascular Content (µg/g)
OTA in 
Normal Kidney 
(µg/g) 
OTA in 
Perfused 
Kidney (µg/g) 
Perfusion 
Efficiency 
(%) 
Illustrated 
in Figure 1
Female       
18.1 10 2.5 3.2 0.27 90.5 C,D 
11.8 6.5 1.6 1.8 1.16 37  
13.3 7.3 1.8 1.6 0.26 83.1 C,D 
18.2 10 2.5 1.9 0.14 92.6 C,D 
12.0 6.5 1.65 2.7 0.19 92.9 C,D 
Mean ± SD 8.1 ± 1.8 2.01 ± 0.41 2.24 ± 0.61 0.40 ± 0.43 79.2 ± 23.9  
Male       
14.6 8.0 2.00 2.25 0.36 84.2 C,D 
16.4  9.0 2.25 2.69 1.58 41.2  
21.2 11.6 2.91 2.63 1.31 50.3 B 
17.2 9.5 2.36 3.02 1.22 59.7 B 
23.6 13.0 3.24 1.89 0.08 95.9 C,D 
14.8 8.2 2.04 2.25 0.03 98.4 C,D 
Mean ± SD 9.9 ± 2.0 2.47 ± 0.50 2.46 ± 0.37 0.76 ± 0.68 71.6 ± 24.4  
In females, the plasma OTA concentration was in the range 12–18 μg/mL and kidney perfusions 
had generally been quite efficient (mean 79%). All perfused kidneys still contained a measurable amount 
of OTA, which is to be expected since perfusion could not be expected to be perfect. Additionally, 
some OTA must have remained within nephron epithelia, already destined for metabolism to ochratoxin 
alpha and subsequent excretion, and, therefore, was unaffected by vascular perfusion. Conversion of 
plasma OTA values to whole blood (assuming a standard 55% plasma component in blood [7]) before 
translation into an amount equivalent to that in kidney vasculature assuming a 25% compartment in 
kidney, gave a group mean value (2.01 ± 0.41 μg/mL) that quite closely matched the mean of the measured 
OTA value in kidneys (2.24 ± 0.61 μg/mL). These complementary findings support the conclusion that 
a large proportion of the OTA in kidney of these animals resided within the vascular compartment.  
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Figure 1. Kidney perfusion efficiency in rats receiving dietary ochratoxin A; contrasting 
sections stained with haematoxylin and eosin. (A) Not perfused; medullary blood vessels 
filled with erythrocytes (arrows); (B) Moderately efficient perfusion; numerous erythrocytes 
(arrows) in the medullary blood vessels; (C) Efficiently perfused kidney, no erythrocytes in 
the cortical blood vessels and glomeruli; (D) Efficiently perfused kidney; medullary blood 
vessels empty. Bar = 100 μm. 
Similarly, in males, in which plasma OTA values (14–23 μg/mL) were a little higher than in the 
females, perfusion had also been quite efficient (mean 72%) and a little residual OTA was consistently 
detected after perfusion. OTA measured in whole kidneys (mean 2.46 μg/mL) was not significantly 
different from that in females. In addition, notably, the somewhat higher OTA content of feed given to 
the male rats did not disproportionately increase the measured OTA in either perfused or non-perfused 
kidneys. Application of a notional 25% vascular component for a kidney gave a remarkably close 
estimate of the non-perfused kidney content of OTA.  
3. Discussion 
Within the limitations of whole body perfusion technique and analytical efficiency for very small 
amounts of OTA in rat plasma and kidney, the present findings demonstrate that a very substantial 
proportion of the OTA in kidneys, when chronic OTA intake has reached a steady state in blood, is 
readily removable by vascular perfusion. Seven of the eleven present perfusions showed >80% 
difference between OTA content of pairs of perfused and non-perfused kidneys. That pharmacokinetic 
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equilibrium would, from our experience, likely to be unilaterally carcinogenic for kidneys in a 
significant proportion of males after about nine months of continuous dietary exposure, slowly 
delivering ~30 mg of toxin [8,9]. A substantial proportion of this toxin will be excreted via kidney, 
with access to nephron epithelia by organic anion transporters and/or glomerular filtration. That 
currently seems more a matter of conjecture and has very little experimental demonstration. With a 
vast number of OTA molecules necessary to pass though a kidney to generate a lone cell in the OSOM 
with a significant mutation, it is probably impossible to track its origin. However, the recognition of 
putative pre-neoplastic nephron fragments by immunohistochemical histology [10] points to a source 
of early malignancy from which transformed cells could be obtained for molecular genetic analysis. 
Application of the present study to several aspects of ochratoxicosis and associated publications can 
be made. A study in piglets, given dietary OTA for four weeks (118 ng/g in feed) [11], plasma OTA 
values at completion matched sympathetically with the OTA concentration in kidney and allowed the 
conclusion that reducing the OTA level in blood leads to its decrease in kidney. Applying the present 
principle, we note that if the pig renal vasculature was an ~28% component, it would have accounted 
for the whole OTA content of kidney. 
In a very recent study [12], pubertal male Fischer rats (200 g) were given OTA-contaminated  
(10 µg/g) feed for six days in metabolism cages, twice the highest dose quoted in [13]. OTA had then 
reached 11 µg/mL in plasma and 1.44 µg/g in kidney, allowing a correlation calculated for the present 
context to equate to kidney OTA being exclusively in the vascular compartment if the latter had been 
only 23% of the organ. Further, OTA in brain, at a concentration of only 0.13 µg/g, pointed to the 
well-known and much smaller (~2%) vascular compartment of that organ. Nevertheless, authors 
clearly had great difficulty in explaining their findings, with reference to literature on mechanism, 
concluding that glomerular excretion of OTA was limited because of its high binding to plasma protein 
and that the high concentration in kidney is because it is a target for toxicity. 
At first sight, inconsistency with the present findings is apparent in a gene-expression study [14],  
in which OTA concentration in plasma and kidney are defined purely as context for male rats gavaged 
daily (0.5 mg/kg b.w.) for up to three weeks. Applying the present principles to estimate kidney 
content only for a notional 25% vascular compartment in vivo, excluding any residence in renal 
parenchyma, reveals a 40%–45% shortfall. We attribute this partly to kidney harvest after loss of 
vascular turgor, while blood leaks due to capsule elasticity and partly due to volume losses during 
cutting, washing, and weighing tissue pieces before freezing in liquid nitrogen. Similarly, from the 
same laboratory [15], measurement of OTA content of kidney may not attain its full potential for 
estimating the proportion of OTA in renal parenchyma unless the vascular supply is first ligated under 
normal blood pressure, and blood allowed to clot in situ. However, this may not be compatible with a 
research objective. Notably, in a rat experiment [16], analogous to that in pigs from the same 
laboratory above [11], similar blood leakage and tissue freezing may explain the apparent shortfall in 
kidney OTA relative to that in plasma.  
The present findings can also be applied to the OTA pharmacokinetic study [17] in which excised 
rat kidneys were uniquely flushed with saline. Since flushing of female kidney reduced renal OTA 
content by 90% from the ‘expected’ value, as by in situ perfusion in the present study, it is notable that 
the same technique in males achieved only a 42% reduction. For a single gavage dose on a body 
weight basis, and where males were much larger than females, we suggest that flushing of larger 
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excised male kidneys via the renal artery may be less efficient. Therefore, perception of OTA 
“accumulation” in male kidneys in these circumstances, and implication for toxicology, may have  
been insecure.  
Recent combined application of LC-MS analysis of ochratoxin A pharmacokinetics [18] performed 
acute and chronic experiments with Sprague-Dawley male rats. The acute dose 0.2 mg/kg b.w. was 
less than that in [17] (0.5 mg/kg b.w.) but was accompanied by a rather large ethanol component in the 
gavage vehicle. Correspondingly, the maximum plasma concentration (nearly 2 μg/mL) was less than  
in [17] (4.3 μg/mL), although achieved by 2 h and 4 h, respectively. Maximum concentration in several 
organs occurred at 4 h, in descending order kidney (400 ng/g, corresponding to nearly 2 μg/mL in 
plasma), lung, liver and heart, spleen, brain. By five days, OTA pharmacokinetics had stabilised, 
possibly as the ethanol influence subsided. In the new slower kinetics, measured OTA in plasma  
(~300 ng/mL) correlated closely with that in kidney (~45 ng/g) assuming a 25% vascular compartment. 
In the chronic dosing experiment [18], organ analysis after 20 days of OTA exposure (0.1 mg/kg b.w.) 
gave an interesting rank order of OTA content, different from that after a single dose, namely lung, 
liver, heart and kidney, in descending order from 96 to 56 ng/g. Unfortunately, no plasma value is 
given and so authors missed a potential opportunity to deduce any connection(s) between organ OTA 
content and its vascularity. However, the rank change from kidney in top place after an acute dose is 
not surprising since lung is very highly vascular and has no excretory feature, whereas kidney provides 
an important and dynamic excretory and degradative function for OTA. 
The present study also has wider implications. We similarly find the literature unclear concerning  
in vivo mechanism(s) in OTA transfer from renal vasculature to nephron epithelia. For example,  
a recent review [19] concludes that glomerular filtration is irrelevant because of the high degree of 
binding of OTA to plasma proteins. Therefore, the complex organic anion transfer (OAT) mechanism, 
on which much has been published particularly on in vitro studies in the last decade, is the way of 
renal excretion for OTA. However, we note that this trans-membranes concept requires transfer across 
both capillary wall and the basal membrane of nephrons and is energy-consuming, whereas escape of 
free OTA molecules through the semi-permeable fenestrations in the glomerular capillary cluster is 
easy, as it is for many small molecules for which crucial rescue and salvage mechanisms in renal 
proximal tubules sustain mammalian life. It is therefore impossible to ignore the glomerular excretion 
of OTA, and there is no experimental study to show the relative participation of any other excretory 
mechanism within kidney for this molecule. 
Further concerning organic anion transmission, high affinity binding of OTA to plasma proteins is 
unlikely to be reversed while blood traverses peri-tubular cortical capillaries and glomeruli. 
Additionally notable, small plasma proteins (estimated size, 20 KDa) were recognised 30 years ago as 
binding OTA [20] and that magnitude of lipocalin molecule certainly passes through male rat glomerular 
filtration into urine [21], and could be involved in OTA excretion into the nephron lumen, bound to an 
α2u-globulin [22]. Ultimately, Anzai et al. [19] conclude that organic anion transporter function 
contributes to OTA accumulation in kidney. We have difficulty with this statement in view of the 
present findings, preferring to focus on mechanism of accumulation in blood, from which other 
apparent “accumulations” appear automatically in whole organ analysis when blood in vasculature  
is ignored.  
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The present equivalence of perfusion efficiency in both male and female rats does not obviously 
support the contention [1] that sex-hormone-dependent preferential uptake of OTA into proximal 
tubule cells via apical and basolateral organic anion transporters accounts for OTA accumulation in 
males as a key event in carcinogenicity. This is in a context, with selective use of literature, of citing 
the 2006 European Food Safety Authority opinion [23] that OTA has insufficient DNA reactivity for 
renal tumour formation, while ignoring the accessible description of an adduct structure already 
published [24].  
Demonstration of the quantitative role of OTA as a vascular component extends logically, in kidney 
of rats exposed throughout adult life to OTA, to adducts with DNA that were recognised on  
2D-chromatograms after 32P-postlabeling [25]. A few kidneys contained adenocarcinomas; adduct 
incidence throughout was of single or double digit amounts per 109 nucleotides, demonstrating that 
OTA is a genotoxin. Subsequent attempts have been made to demonstrate contrarily a non-genotoxic 
tumourigenic mechanism for OTA [26,27], and there is conflicting interpretation of analytical 
methodology [28]. Several mechanisms have been studied, but even in [29], linked to a lifetime rat 
study, the gene-expression changes amongst four rats are difficult to link with carcinogenicity when 
there was only 25% tumour incidence. Subsequently, the model adduct C–C8 OTA 3'dGMP, formed  
semi-synthetically, was shown to co-chromatograph with the principal natural adduct derived from 
OTA-exposed rat kidney processed by 32P postlabeling [24]. Assuming, therefore, that OTA-DNA 
adducts do exist, albeit temporarily in vivo, it is important to know where they are and where incorrect 
repair might impose tumourigenic risk. This is important for understanding both experimental  
OTA-derived renal cancer in rats and also idiopathic human renal cancer that has never been attributed 
clearly to OTA. Detection of OTA-DNA adducts in blood has recently been reported for rats [30]. 
Since blood contains nucleated leukocytes they may reasonably contain adducts from circulating OTA; 
their contribution to kidney adducts could, therefore, be calculated to assess adducts in renal parenchyma. 
Detection of DNA-OTA adducts in testis of mice given OTA [31] is not surprising, particularly 
concerning one co-chromatographing with C–C8 OTA 3'dGMP. Adducts in kidney and testis of  
new-borns, sourced via placental transfer from OTA-treated mothers; lower incidence in testis is 
consistent with its less vascularised structure. Indeed, were there any vascularised tissues without 
adducts? Nevertheless, limited evidence of exposure is hardly predictive of toxicological outcome at 
the short and relatively high artificial OTA exposure, especially since no direct connection between 
adducts and the initiation of OTA- derived experimental renal cancer is yet available. That OTA is  
“a biologically plausible cause of testicular cancer in man” [32] seems premature since authors omit to 
cite both the consistently-negative rat and mouse evidence (e.g., [33]) and the immunohistochemical 
differentiation of tumour in testis and kidney in experimental OTA oncology in rats [10]. 
The plant nephrotoxin aristolochic acid 1 forms four DNA adducts, in abundance more prominent 
than with OTA, but which appear to be much more persistent [34]. Blood seems not to have been 
studied, but could define their location in urinary tract parenchymal epithelia concerning experimental 
tumourigenesis and in humans, whether from misuse of herbal medicaments, or in traditional 
ethnobotanical usage or other undefined putative exposure in Balkan nephropathy hotspots. There is 
also the elusive silent nephropathic metabolite of the common food-borne mould Penicillium polonicum, 
causing rat renal apoptosis and one DNA adduct [35]. Chronic ingestion results in striking karyomegaly 
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in the outer stripe of the outer medulla [36], a histopathological feature of topical interest also for OTA 
carcinogenicity [37]. 
In concluding that OTA measured in whole kidney may mostly be attributable to that in the vascular 
compartment, it follows that detection of DNA-OTA adducts in kidney, and in kidney tumours of 
humans and experimental animals, may also need careful re-interpretation, while still being a general 
indicator of exposure to the toxin. Assuming that, for example in male rats, adducts can be 
demonstrated specifically in nephron epithelia, a very low incidence of adduction, even below the 
current limit of detection, may be entirely sufficient so as, predictably via mis-repair, a single tumour 
might be initiated after many months of OTA insult. The obligatory long half-life characteristic of 
OTA in plasma [38] might provide the continuity of delivery to proximal tubule epithelia, even 
through intermittent dietary exposure, but this has not yet been tested  
4. Materials and Methods 
4.1. Animals, Housing Conditions and Experimental Procedure 
Wistar rats (16 weeks old), from the Akdeniz University Animal Experiment Unit, were housed on 
sawdust bedding in groups of 4–5 in polycarbonate cages with stainless steel covers. Room 
temperature was maintained at 22 ± 2 °C with a relative humidity of 55% ± 10% and a day/night cycle 
of 12 h. Six males (average weight 300 g) and 5 females (average weight 210 g) were given 
experimental feed prepared by homogenizing standard rat diet with the same OTA-rich fermentation 
product (6 mg OTA g−1) as used previously [9] to provide 3 and 5 µg OTA g−1-contaminated feed for 
females and males, respectively. Rats were given 20 g feed/rat/day in stainless steel containers, and 
water ad libitum. The physical condition of each rat was assessed daily for any obvious clinical signs. 
The study was approved by Akdeniz University Local Animal Research Ethics Committee. The 
experiment continued for at least 2 months to achieve, from experience [13], an OTA concentration in  
circulating blood sufficient for meaningful measurements in plasma and kidneys but without any 
adverse clinical effect. 
4.2. Kidney Perfusion 
Perfusion was performed under physiological blood pressure (10–12 mm Hg) which was 
maintained by a peristaltic pump delivering physiological saline (50–60 mL) at 10–14 mL/min.  
The rats were prepared for in situ perfusion of left kidney by anaesthetizing with sodium 
pentobarbital (50 mg/kg, intra peritoneal). After induction of anaesthesia, median laparotomy was 
performed for explosion of abdominal cavity and the right and left kidneys. The abdominal aorta was 
exposed by deflection of the intestines to the right side of the animal and dissected above and below 
the renal vessels. A loose tie was placed to the aorta above the renal arteries and below the superior 
mesenteric artery. For left kidney perfusion, a cannula was placed to the aorta above the genital 
arteries and tightly fixed in order to avoid any leakage of perfusion solution and consequent  
pressure lost.  
Prior to left kidney perfusion, the right kidney artery and vein were tied together close to the kidney. 
The loose tie between the renal arteries and below the superior mesenteric artery was tied just before 
Toxins 2015, 7 1013 
 
the perfusion solution was pumped to the aorta. Immediately after pumping the perfusion solution,  
the vein of the left kidney was cut close to the kidney for removal of the blood and perfusion solution. 
Blood pressure of rats was measured with a pressure transducer connected to the cannula and a 
blood pressure recorder. The same system was also used for the measurement of perfusion pressure. 
Abdominal aorta blood pressure in the rats was found to vary between around 10–12 mm Hg.  
A continuous flow peristaltic pump was used for transfer of perfusion solution. To maintain the 
perfusion pressure within the above physiological blood pressure range, the flow rate was set to  
10–14 mL/min. About 50–60 mL of lactated Ringer’s solution was used for perfusion of the kidney.  
During perfusion, a change in colour of the left kidney, adjacent bowels and parenchyma was 
observed. Such changes were indicative of effective perfusion. Occasionally, technical problems such as 
displacement of the cannula from the aorta during perfusion or leakage of perfusion solution from 
aorta to upper part of body result in less efficient kidney perfusion by partial diversion of perfusate 
towards liver, lungs and brain. Consequently, less marked colour change during perfusion occurred in 
two out of six males and one out of five females, implying partial perfusion (Figure 1, Table 1). 
Nevertheless, all perfusions were included in the study. 
After perfusion of the left kidney, both kidneys were removed and about a quarter of each kidney 
was put into 10% formaldehyde for histological analysis. The remaining three-quarters of each kidney 
was stored at −40 °C for OTA analysis. 
4.3. OTA Extraction from Kidneys and Plasma 
Frozen kidney (200–300 mg for non-perfused kidney and 350–450 mg for perfused kidney) was cut 
in small pieces and placed in 1 mL of 50 mM sodium phosphate buffer (pH 6.5) and and homogenized 
(Heildoph Silentcrusherm) for 1 min at 15,000 rpm. The homogeniser probe was washed between 
samples with water and rinsed with ethanol to prevent cross-contamination. Homogenates were kept at 
−40 °C for at least one day and then thawed at room temperature for 30 min. before OTA extraction. 
Ice-cold absolute ethanol (400 μL) and 20% trichloroacetic acid (50 μL) were added to 250 μL of  
tissue homogenate.  
For plasma OTA extraction, 20 μL sample was added to 540 μL of extraction solution  
(20% trichloroacetic: ice-cold absolute ethanol, 1:8, v/v). The mixture was vortexed for 1 min and  
kept at room temperature for 15 min while mixing occasionally. The mixture was centrifuged at 9600 g  
for 10 min at 4 °C.  
When necessary, the supernatant of organ or plasma extraction was diluted with  
(20% trichloroacetic acid: sodium phosphate buffer: absolute ethanol, 1:5:8 v/v) to obtain an OTA 
concentration in the range 1–50 ng mL−1. All samples were filtered using regenerated membrane filters 
(pore size 0.4 μm and disk size 4 mm, Corning) before HPLC injection. 
4.4. OTA Analysis of Samples  
OTA analyses were carried out in an accredited Turkish Research Council Food Quality Centre 
(TÜBİTAK-MAM, Gebze, Turkey) where residual mycotoxin analyses are performed on foods using 
validated methods. HPLC analyses were performed with a Shimadzu LC-20A liquid chromatographic 
system equipped with a fluorescence detector (RF-20A, Shimadzu HPLC, Kyoto, Japan). OTA was 
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analysed on a 5 μm (15 cm × 0.4 cm) Tracer Extrasil ODS2 column (Thermo, Thermo Scientific, 
Waltham, MA, USA). The mobile phase was 29:29:42 (v/v) methanol-acetonitrile-sodium acetate  
(5 mM acidified to pH 2.6 with phosphoric acid); solvents were HPLC grade. The injection volume 
was 100 μL and flow rate was 1.5 mL/min. Chromatography was performed at 40 °C and monitored by 
fluorescence detection after optimising the excitation (333 nm) and emission (443 nm) wavelengths. 
Limits of detection (LOD) and quantification (LOQ) were 0.37 and 1 ng/mL, respectively, and OTA 
recovery for plasma and organs was 97% and 92%–96%, respectively.  
4.5. Histological Examination for Perfusion Efficiency 
Kidney samples (perfused and non-perfused) were collected during necropsy, fixed in 10% neutral 
buffered formalin and embedded in paraffin. Sections (5 μm) were stained with haematoxylin and eosin. 
5. Conclusions 
Analysis of perfused and non-perfused kidneys of rats with chronic, tolerable, circulating OTA from 
dietary exposure has demonstrated, for the first time, that most of the toxin resides in the well-defined 
vascular compartment. Consequently, focus should be on plasma protein-bound OTA, readily 
quantified, rather than on an artefact of apparent preferential accumulation in kidney. Recognition that 
most of the OTA in kidney in vivo can be in transit and toxicologically inert there emphasizes the need 
for better understanding of both whole body and organ pharmacokinetics of dietary OTA. Current 
neglect of the nucleate component of blood as a reservoir of nephrotoxin-DNA adducts, also in transit, 
may require reassessment of the significance of such adducts of, for example, OTA and aristolochic 
acid detected in healthy or malignant kidney. 
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